14 Sep 2017

(518 votes)

How You Can Benefit From Rigvir® for Glioblastoma: Brief History and Recent Studies

The latest published studies in Melanoma Research, a medical journal, dated October 2015, claim that Rigvir® is able to raise the survival rates of virotherapy patients 4.39–6.57-fold [1]. Now you may be asking yourself about the reasons for such success rate. Let’s find out.

oncolytic virotherapy glioblastoma

A patient is getting ready to receive Rigvir® injection

Riga virus (Rigvir®) was designed in the middle of the 20th century by Aina Muceniece, an immunologist from Latvia. She discovered ECHO-7 virus in babies digestive system, and it became the key component of Rigvir®. The invention of the drug marked an advent of a new cancer treatment method, virotherapy, which is fully based on applying oncolytic viruses.

At the beginning, the medicine targeted only melanoma patients – they were the first to receive the treatment. Shortly after that, the clinical experience showed that Rigvir® is able to help fight the following types of cancer:

Wondering about how Rigvir® fights tumours? It’s that simple: the medicine is injected into your body detecting malignant cells. Then oncotropism takes place – the process of penetrating inside a cell. Once inside, Rigvir® eliminates the cancer cell and travels to another one killing the entire tumor.

A unique feature of Rigvir® is almost no side effects. The only after-effect reported was a temperature rise up to 37.5°C/99.5°F that lasted for 3 days. Another reason why an increasing number of cancer patients refer to Rigvir® is that it leaves your healthy cells untouched. This means virotherapy may be applied as the only cancer treatment option as well as a supplement to radiotherapy or chemo.

If you decide to go for virotherapy to treat glioblastoma, note that Rigvir® is registered only in 3 states: Latvia (2004), Georgia (2015), and Armenia (2016). Latvia remains the prominent direction for Rigvir® sale being the most frequently visited virotherapy location throughout Europe.

Before applying, please prepare your medical documentation. This is necessary for the oncologists can first evaluate your case at no charge to see if you qualify for Rigvir® therapy. The assessment takes from 48 to 72 hours while the list of your medical files to be provided normally includes:

  • Histopathological findings
  • Cytological observations
  • Recent blood count, including white blood cells
  • Epicrisis
  • MRI or CT
  • Analysis for ALT and creatinine

On receiving the confirmation of your candidacy for Rigvir® therapy, you’ll also receive further details so you can start planning your trip to Latvia for treatment purposes.

If you or someone you know would like to qualify for Rigvir® therapy and inquire about the cost estimates, click the button below and fill in the form on the right. We'll get back to you within the next 24 hours.


List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.